Streptomyces Patents (Class 435/252.35)
-
Publication number: 20120141487Abstract: The present invention relates to isolated nucleic acid molecules which encode an antigen from a Moraxella catarrhalis (Meat) species, a vector which comprises such nucleic acid molecule, and a host cell comprising such vector. Furthermore, the invention provides antigens from a Moraxella catarrhalis species, as well as fragments and variants thereof, a process for producing such antigens, and a process for producing a cell which expresses such antigen. More specifically, such antigens are produced by or associated with bacterial infections caused by Moraxella catarrhalis.Type: ApplicationFiled: May 28, 2010Publication date: June 7, 2012Applicant: Intercell AGInventors: Alexander Von Gabain, Eszter Nagy, Andreas Meinke, Sanja Selak, Markus Hanner, Margarita Smidt, Julia Flor, Birgit Noiges, Wolfgang Schueler, Ulrike Schirmer, Verena Salletmayer, Mario Aistleithner, Stefan Seidel, Martin Oleksiewicz
-
Publication number: 20120142622Abstract: The present invention relates to Stambomycin compounds, their derivatives and their pharmaceutically acceptable salt thereof.Type: ApplicationFiled: July 23, 2010Publication date: June 7, 2012Applicants: UNIVERSITE HENRI POINCARE NANCY 1, INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE, UNIVERSITY OF WARWICKInventors: Bertrand Aigle, Gregory Challis, Luisa Laureti, Lijiang Song, Pierre Leblond
-
Publication number: 20120142063Abstract: The present disclosure relates to polypeptides having nitrilase activity, polynucleotides encoding the polypeptides, and methods of using the polypeptides.Type: ApplicationFiled: July 22, 2010Publication date: June 7, 2012Applicant: Codexis ,Inc.Inventors: Anke Krebber, Emily Mundoff, Marissa Mock, Spiros Kambourakis
-
Publication number: 20120142979Abstract: Compositions and methods for production of fatty alcohols using recombinant microorganisms are provided as well as fatty alcohol compositions produced by such methods.Type: ApplicationFiled: November 22, 2011Publication date: June 7, 2012Applicant: LS9, INC.Inventors: Jay D. KEASLING, Zhihao Hu, Chris Somerville, George Church, David Berry, Lisa Friedman, Andreas Schirmer, Shane Brubaker, Stephen B. Del Cardayre
-
Publication number: 20120135477Abstract: The invention relates to a process for the biocatalytic production of ambroxan by means of a polypeptide with the activity of a homofarnesol-ambroxan cyclase, which are a novel class of enzymes.Type: ApplicationFiled: June 2, 2010Publication date: May 31, 2012Applicant: Basf SEInventors: Michael Breuer, Andrea Hörster, Bernhard Hauer
-
Publication number: 20120135912Abstract: The invention provides novel 2D-VCAM-1 variant polypeptides and conjugates thereof that bind human VLA4. The invention also provides related polynucleotides, compositions, vectors, host cells, and methods.Type: ApplicationFiled: May 10, 2011Publication date: May 31, 2012Applicant: PERSEID THERAPEUTICS LLCInventors: MADAN M. PAIDHUNGAT, AMULYA NANISETTI, THOMAS BOUQUIN, KIM VILBOUR ANDERSEN, STEVEN J. CHAPIN, CLAUS KREBBER, RONG A. FAN, DANIEL MALASHOCK, AMY BRIDEAU-ANDERSEN, ERIK KARRER, BRUCE DEVENS, STEVEN H. BASS
-
Publication number: 20120135463Abstract: Vectors expressible in a host that is the rhaBAD promoter region of the L-rhamnose operon operably linked to a transcriptional unit that is: a) a nucleic acid sequence which is heterologous to the host, and b) a prokaryotic signal sequence operably linked to the nucleic acid sequence. The prokaryotic signal sequence is selected from signal peptides of periplasmatic binding proteins for sugars, amino acids, vitamins and ions. The expression of the nucleic acid sequence is controlled by the promoter region. The vector is used for the regulated heterologous expression of a nucleic acid sequence in a prokaryotic host. This is an isolated and purified nucleic acid sequence expressible in a host is the promoter region of the L-rhamnose operon. There is a method for producing a polypeptide in a host using the vector.Type: ApplicationFiled: October 14, 2011Publication date: May 31, 2012Inventors: Johann Brass, Christoph Kiziak, Joachim Klein, Ralf Ostendorp
-
Publication number: 20120128689Abstract: The present invention relates to antigen binding proteins to human IL-23, pharmaceutical formulations containing them and to the use of such antigen binding proteins in the treatment and/or prophylaxis of inflammatory diseases such as Rheumatoid Arthritis (RA).Type: ApplicationFiled: March 30, 2010Publication date: May 24, 2012Applicant: Glaxo Group LimitedInventors: Jane Elizabeth Clarkson, Ruth McAdam, Alan Peter Lewis
-
Publication number: 20120128677Abstract: The present invention provides a method for diagnosing and detecting diseases associated with pancreas. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in pancreatic diseases (PCAT) and antibodies binds to PCAT. The present invention provides that PCAT is used as targets for screening agents that modulates the PCAT activities. Further, the present invention provides methods for treating diseases associated with pancreas.Type: ApplicationFiled: May 4, 2011Publication date: May 24, 2012Applicant: CELERA CORPORATIONInventors: Bruno DOMON, Ian MCCAFFERY, Vaibhav NARAYAN, Scott PATTERSON
-
Publication number: 20120128669Abstract: Amino acid sequences are provided that are directed against and/or that can specifically bind protein F of hRSV, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The amino acid sequences, polypeptides and therapeutic compounds and compositions provided by the invention show an improved stability, less immunogenicity and/or improved affinity and/or avidity for protein F of hRSV. The invention also relates to the uses of such amino acid sequences, polypeptides, compounds or constructs for prophylactic and/or therapeutic purposes.Type: ApplicationFiled: June 7, 2010Publication date: May 24, 2012Applicant: Ablynx N.V.Inventors: Erik Depla, Catelijne Stortelers, Stephanie Staelens
-
Publication number: 20120122171Abstract: The invention provides a non-naturally occurring microbial biocatalyst including a microbial organism having a 4-hydroxybutanoic acid (4-HB) biosynthetic pathway having at least one exogenous nucleic acid encoding 4-hydroxybutanoate dehydrogenase, succinyl-CoA synthetase, CoA-dependent succinic semialdehyde dehydrogenase, or ?-ketoglutarate decarboxylase, wherein the exogenous nucleic acid is expressed in sufficient amounts to produce monomeric 4-hydroxybutanoic acid (4-HB).Type: ApplicationFiled: January 11, 2012Publication date: May 17, 2012Applicant: GENOMATICA, INC.Inventors: Mark J. Burk, Stephen J. Van Dien, Anthony P. Burgard, Wei Niu
-
Publication number: 20120122184Abstract: A new strain Bacillus sp. P203 (Bacillus plakortiensis) is disclosed. Isolated mature functional polypeptide which is obtainable from the bacterium strain Bacillus sp. P203 deposited under accession number DSM 17419 are disclosed.Type: ApplicationFiled: January 26, 2012Publication date: May 17, 2012Applicant: NOVOZYMES A/SInventors: Preben Nielsen, Reinhard Wilting, Martin Borchert
-
Publication number: 20120114659Abstract: Monoclonal antibodies that act as potentiators, stimulators and agonists of guanylyl cyclase receptors are disclosed.Type: ApplicationFiled: November 17, 2009Publication date: May 10, 2012Applicants: MORPHOSYS AG, BOEHRINGER INGELHEIM PHARMACEUTICALS INC.Inventors: Alisa Waterman, Daniel Rajotte, Tobias Litzenburger, Alexandra Kraus
-
Publication number: 20120115134Abstract: We have discovered a protein in humans, herein referred to as collagen like gene (CLG) product (SEQ ID NOS: 12 and 13), that is expressed in human prostate cancer and breast cancer cell lines but not in normal adult, placenta, lung, liver, skeletal muscle, kidney or pancreas tissues. We have also discovered that the level of CLG mRNA expression correlates positively with the metastatic potential of the cancer cell lines tested.Type: ApplicationFiled: July 12, 2011Publication date: May 10, 2012Applicant: Children's Medical Center CorporationInventors: Bruce R. Zetter, Lere Bao, Jacqueline Banyard
-
Publication number: 20120114799Abstract: The invention relates to Citrobacter phytases derived from Citrobacter amalonaticus, Citrobacter gillenii, and related phytases. The phytases belong to the acid histidine phosphatase family, are acid-stable, and expectedly of a high specific activity. The invention also relates to the corresponding DNA, the recombinant and wild-type production of the phytases, as well as the use thereof, in particular in animal feed.Type: ApplicationFiled: November 3, 2011Publication date: May 10, 2012Applicant: Novozymes A/SInventors: Monica Takamiya Wik, Carsten Sjøholm
-
Publication number: 20120107899Abstract: The present invention relates to use of Caminibacter carbonic anhydrase in CO2 extraction, e.g., from flue gas, natural gas, biogas or ambient air. The Caminibacter carbonic anhydrases are especially well suited for these purpose due to their extreme thermostability.Type: ApplicationFiled: June 25, 2010Publication date: May 3, 2012Applicants: NOVOZYMES NORTH AMERICA, INC., NOVOZYMES A/SInventors: Martin Borchert, Paria Saunders
-
Publication number: 20120100140Abstract: A method of producing Fc-containing polypeptides, such as antibodies, having stabilized Fc regions is provided, together with stabilized Fc polypeptides produced according to these methods as well as methods of using such antibodies as therapeutics.Type: ApplicationFiled: January 22, 2010Publication date: April 26, 2012Applicant: BIOGEN IDEC MA INC.Inventors: Christopher L. Reyes, Eric Chan, Frederick R. Taylor, Ellen Garber, Brian Robert Miller, Stephen Demarest, Scott Glaser
-
Publication number: 20120102588Abstract: Provided are zinc finger protein transcription factor DST having the amino acid sequence as shown in SEQ ID NO: 2, conservative variants and homologous polypeptides thereof. Also provided are DNA sequence encoding the transcription factor DST, vector or host cell comprising the DNA sequence, cis-acting element binding to the DST, inhibitor or non-conservative variant of the transcription factor DST or encoding sequence thereof, and use of the inhibitor or non-conservative variant for improving the drought and salt tolerance in plant.Type: ApplicationFiled: April 7, 2010Publication date: April 26, 2012Applicant: SHANGHAI INSTITUTES FOR BIOLOGICAL SCIENCES, CASInventors: Hongxuan Lin, Xinyuan Huang, Daiyin Chao, Jiping Gao, Meizhen Zhu, Min Shi
-
Publication number: 20120100581Abstract: The invention provides novel polypeptides having phospholipase activity, including, e.g., phospholipase A, B, C and D activity, patatin activity, phosphatidic acid phosphatases (PAP)) and/or lipid acyl hydrolase (LAH) activity, nucleic acids encoding them and antibodies that bind to them. Industrial methods, e.g., oil degumming, and products comprising use of these phospholipases are also provided.Type: ApplicationFiled: April 20, 2011Publication date: April 26, 2012Applicant: VERENIUM CORPORATIONInventors: SVETLANA GRAMATIKOVA, GEOFF HAZLEWOOD, DAVID LAM, NELSON R. BARTON, BLAKE G. STURGIS, DAN E. ROBERTSON, JINCAI LI, JOEL A. KREPS, RODERICK JAMES FIELDING, ROBERT C. BROWN, AMIT VASAVADA, XUQIU TAN, ADRIAN BADILLO, WILHELMUS P. VAN HOEK, GISELLE JANSSEN, CHARLES ISAAC, MARK J. BURK
-
Publication number: 20120100596Abstract: The present invention relates to isolated polypeptides having organophosphorous hydrolase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: ApplicationFiled: May 6, 2010Publication date: April 26, 2012Applicant: NOVOZYMES A/SInventors: Steffen Danielsen, Lars Kobberoee Skov, Ricardo Leite, Vincent Laize, M Leonor Cancela Da Fonseca
-
Publication number: 20120100139Abstract: This disclosure provides a multi-specific fusion protein composed of a CD86 antagonist binding domain and another binding domain that is an IL-10 agonist, an HLA-G agonist, an HGF agonist, an IL-35 agonist, a PD-1 agonist, a BTLA agonist, a LIGHT antagonist, a GITRL antagonist or a CD40 antagonist. The multi-specific fusion protein may also include an intervening domain that separates the other domains. This disclosure also provides polynucleotides encoding the multi-specific fusion proteins, compositions of the fusion proteins, and methods of using the multi-specific fusion proteins and compositions.Type: ApplicationFiled: October 2, 2009Publication date: April 26, 2012Applicant: Emergent Product Development Seattle, LLCInventors: Peter Armstrong Thompson, Peter Robert Baum, Philip Tan, John W. Blankenship, Sateesh Kumar Natarajan
-
Publication number: 20120093788Abstract: We have identified by molecular cloning a protease which originates from the larvae of Lucilia sericata and which was termed debrilase due to its activities useful for debridement of wounds.Type: ApplicationFiled: March 3, 2010Publication date: April 19, 2012Applicant: B.R.A.I.N. Biotechnology Research and Information Network AGInventors: Frank Niehaus, Jürgen Eck, Renate Schulze, Michael Krohn
-
Publication number: 20120094329Abstract: The disclosure provides methods and materials for increasing the expression of a protein of interest such as an antibody by a cell. ABC50 expression or activity is increased which increases expression of the protein or antibody of interest. The disclosure also provides methods and materials for increasing the sensitivity of a cell to an endoplasmic reticulum stress agent such as Econozole by decreasing the level of ABC50.Type: ApplicationFiled: May 5, 2010Publication date: April 19, 2012Applicant: UNIVERSITY HEALTH NETWORKInventor: Stuart A. Berger
-
Publication number: 20120093811Abstract: The invention relates to an isolated antibody that specifically binds vascular endothelial growth factor-D (VEGF-D) and to a humanized antibody that specifically binds VEGF-D.Type: ApplicationFiled: April 1, 2010Publication date: April 19, 2012Inventors: Jason W. Simmonds, Andrew J. Pow, Vincent Emil W. Batori, Irene Koukoulas, George Kopsidas
-
Publication number: 20120095193Abstract: Provided herein are isolated antigen binding protein comprising at least one first immunoglobulin variable domain capable of binding to human ADAMTS5. Also provided are antigen binding proteins of the present invention that are monoclonal antibodies, pharmaceutical compositions comprising said antigen binding proteins and methods of treatment.Type: ApplicationFiled: July 1, 2010Publication date: April 19, 2012Inventors: Michael Neil Burden, Paul Andrew Hamblin, Jonathan David Larkin, John Richard White
-
Publication number: 20120088288Abstract: The present invention relates to methods for producing variants of a parent TY145 subtilase and of a parent BPN? subtilase and to TY145 and BPN? variants having altered properties as compared to the parent TY145/BPN? subtilase.Type: ApplicationFiled: November 28, 2011Publication date: April 12, 2012Applicant: NOVOZYMES A/SInventors: Allan Svendsen, Henriette Draborg
-
Publication number: 20120090054Abstract: The present invention relates to isolated polypeptides having endoglucanase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides.Type: ApplicationFiled: December 19, 2011Publication date: April 12, 2012Applicants: Novozymes, Inc., Novozymes A/SInventors: Paul Harris, Elena Valsenko, Elizabeth Zaretsky, Marcus Sakari Kauppinnen
-
Patent number: 8153412Abstract: Variants of Bacillus sp. TS-23 strain alpha-amylases exhibit improved enzymatic performance, including increased themostability, reduced calcium dependence, increased washing/cleaning performance, and baking ability. Compositions comprising these variants are useful in methods of starch processing, starch liquefaction, fermatation, starch saccharification, cleaning, laundrying, textile desizing, baking, and biofilm removal.Type: GrantFiled: November 3, 2008Date of Patent: April 10, 2012Assignee: Danisco US Inc.Inventors: Claudine Y. Chang, Clement Choy, Melodie Estabrook, Mansi Goyal, Thomas P. Graycar, Victoria E. Huang, Brian E. Jones, Marc Kolkman, Karsten M. Kragh, Chris Leeflang, Scott D. Power, Sandra W. Ramer, Andrew Shaw, Casper Vroemen, Walter Weyler
-
Publication number: 20120082996Abstract: IL-21 variants nucleic acid sequences are provided that encode a peptide having deletions and zero to ten conservative amino acid substitutions in the region of amino acid residues 65-96 of SEQ ID. NO:2.Type: ApplicationFiled: September 19, 2011Publication date: April 5, 2012Inventors: Siv Annegrethe Hjorth, Kent Bondensgaard, Dennis Madsen
-
Publication number: 20120082680Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.Type: ApplicationFiled: September 23, 2011Publication date: April 5, 2012Applicant: Merck Sharp & Dohme Corp.Inventors: Ayesha Sitlani, Carl P. Sparrow, Shilpa Pandit, Jon H. Condra, Dana D. Wood, Timothy S. Fisher
-
Publication number: 20120082679Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.Type: ApplicationFiled: September 23, 2011Publication date: April 5, 2012Applicant: Merck Sharp & Dohme Corp.Inventors: Carl P. Sparrow, Ayesha Sitlani, Shilpa Pandit, Jon H. Condra, Holly A. Hammond
-
Publication number: 20120082622Abstract: Isolated polynucleotides encoding Macaca fascicularis CCL17 (CynoCCL17), polypeptides obtainable from expression of these polynucleotides, recombinant cells, and methods of use are disclosed.Type: ApplicationFiled: September 26, 2011Publication date: April 5, 2012Inventors: Michael Naso, Mary Ryan, Sandra Santulli-Marotto, Bethany Swencki-Underwood
-
Publication number: 20120077731Abstract: The present invention relates to amino acid sequences that are directed against/and or that can specifically bind Interleukin-6 Receptor (IL-6R) with improved affinity and/or avidity, and/or that have an improved efficacy and/or potency, and which are capable of (partially, or preferably totally) blocking the IL-6/IL-6R interaction and/or inhibit signalization through IL-6, 1L-6R and/or the IL-6/IL-6R complex. The invention further relates to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.Type: ApplicationFiled: April 12, 2010Publication date: March 29, 2012Applicant: Ablynx N.V.Inventors: Els Anna Alice Beirnaert, Cedric Jozef Neotere Ververken, Joost Alexander Kolkman, Maarten Van Roy
-
Publication number: 20120077964Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.Type: ApplicationFiled: September 27, 2011Publication date: March 29, 2012Applicant: Merck Sharp & Dohme Corp.Inventors: Carl P. Sparrow, Ayesha Sitlani, Shilpa Pandit, Jon H. Condra, Holly A. Hammond
-
Publication number: 20120077273Abstract: The invention provides methods and compositions for inhibiting proliferation of a modified host cell outside of a designated process condition. Compositions and methods for providing a host cell having reduced viability when exposed to natural conditions external to a controlled environment are disclosed.Type: ApplicationFiled: September 21, 2011Publication date: March 29, 2012Applicant: JOULE UNLIMITED TECHNOLOGIES, INC.Inventors: George Church, Frank A. Skraly, Brian D. Green, Jacob C. Harrison
-
Publication number: 20120076799Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.Type: ApplicationFiled: September 23, 2011Publication date: March 29, 2012Applicant: Merck Sharp & Dohme Corp.Inventors: Carl P. Sparrow, Ayesha Sitlani, Shilpa Pandit, Jon H. Condra, Holly A. Hammond
-
Publication number: 20120071419Abstract: The present invention relates to a method for preparing a target-specific non-antibody protein, and more particularly, to a method for preparing a target-specific non-antibody protein comprising the steps of: selecting non-antibody proteins having a structural complementarity with the target site of a target protein in a non-antibody protein library; calculating a binding energy of the selected non-antibody protein and the target protein; selecting a non-antibody protein having a favorable binding energy among the selected non-antibody proteins; selecting amino acid residues having a high binding energy among the interfacial amino acid residues of the selected non-antibody protein and the target protein; and substituting the selected amino acid residues with the amino acid residues having a low binding energy.Type: ApplicationFiled: April 14, 2010Publication date: March 22, 2012Applicant: POSTECH ACADEMY-INDUSTRY FOUNDATIONInventors: Yoon Sup Choi, Jun Ho Chung, Ji Ho Yoo, Hyun Soo Cho, Su Min Yoon, Kyung Lock Kim, Sung Ho Ryu, Sang Uk Kim
-
Publication number: 20120070436Abstract: The present invention relates to antigen binding proteins comprising a receptor-Fc fusion which is linked to one or more epitope-binding domains, methods for making such proteins, and uses thereof.Type: ApplicationFiled: May 26, 2010Publication date: March 22, 2012Inventors: Richard Lewis Easeman, Jonathan Henry Ellis, Paul Andrew Hamblin
-
Publication number: 20120070881Abstract: The present invention relates to an isolated polynucleotide of the complete chromosome of Bacillus licheniformis. The present invention also relates to isolated genes of the chromosome of Bacillus licheniformis which encode biologically active substances and to nucleic acid constructs, vectors, and host cells comprising the genes as well as methods for producing biologically active substances encoded by the genes and to methods of using the isolated genes of the complete chromosome of Bacillus licheniformis.Type: ApplicationFiled: November 28, 2011Publication date: March 22, 2012Applicants: NOVOZYMES A/S, NOVOZYMES, INC.Inventors: Randy Berka, Michael Rey, Preethi Ramaiya, Jens Tonne Andersen, Michael Dolberg Rasmussen, Peter Bjarke Olsen
-
Publication number: 20120070439Abstract: The invention relates to linkers suitable for use in antigen-binding proteins, certain antigen binding proteins and methods of making such proteins and uses thereof.Type: ApplicationFiled: May 26, 2010Publication date: March 22, 2012Inventors: Paul Andrew Hamblin, Alan Peter Lewis, Martin Anibal Orecchia, Radha Shah Parmar
-
Publication number: 20120070868Abstract: Recombinant microbial cells are provided which have been engineered to produce fatty acid derivatives having linear chains containing an odd number of carbon atoms by the fatty acid biosynthetic pathway. Also provided are methods of making odd chain fatty acid derivatives using the recombinant microbial cells, and compositions comprising odd chain fatty acid derivatives produced by such methods.Type: ApplicationFiled: September 14, 2011Publication date: March 22, 2012Applicant: LS9, INC.Inventors: Grace J. Lee, John R. Haliburton, Zhihao Hu, Andreas W. Schirmer
-
Publication number: 20120066781Abstract: This invention relates to phytases, polynucleotides encoding them, uses of the polynucleotides and polypeptides of the invention, as well as the production and isolation of such polynucleotides and polypeptides. In particular, the invention provides polypeptides having phytase activity under high temperature conditions, and phytases that retain activity after exposure to high temperatures. The invention further provides phytases which have increased gastric lability. The phytases of the invention can be used in foodstuffs to improve the feeding value of phytate rich ingredients. The phytases of the invention can be formulated as foods or feeds or supplements for either to, e.g., aid in the digestion of phytate.Type: ApplicationFiled: May 20, 2010Publication date: March 15, 2012Inventors: David P. Weiner, Arne I. Solbak, JR., Ryan McCann
-
Publication number: 20120065380Abstract: The present invention relates to: a dual targeting antibody of a novel form having a water-soluble ligand fused to the N-terminus of a heavy chain or light chain of an antibody; a DNA encoding the dual targeting antibody; a recombinant expression vector containing the DNA; a host cell which is transformed with the recombinant expression vector; a method for preparing the dual targeting antibody by culturing the host cell; and a pharmaceutical composition including the dual targeting antibody.Type: ApplicationFiled: July 22, 2009Publication date: March 15, 2012Applicant: Pharmabcine Inc.Inventors: Jin San Yoo, Weon Sup Lee, Sung Woo Kim, Sang Ryeol Shim
-
Publication number: 20120064622Abstract: The present disclosure identifies pathways, mechanisms, systems and methods to confer chemoautotrophic production of carbon-based products of interest, such as sugars, alcohols, chemicals, amino acids, polymers, fatty acids and their derivatives, hydrocarbons, isoprenoids, and intermediates thereof, in organisms such that these organisms efficiently convert inorganic carbon to organic carbon-based products of interest using inorganic energy, such as formate, and in particular the use of organisms for the commercial production of various carbon-based products of interest.Type: ApplicationFiled: October 31, 2011Publication date: March 15, 2012Applicant: GINKGO BIOWORKSInventors: CURT R. FISCHER, AUSTIN J. CHE, RESHMA P. SHETTY, JASON R. KELLY
-
Publication number: 20120064064Abstract: The present invention relates to antigen binding proteins comprising an immunoglobulin heavy chain and an immunoglobulin light chain, wherein the heavy chain comprises an epitope binding domain linked to the n-terminus of CH1-CH2-CH3, and the light chain comprises an epitope binding domain linked to the n-terminus of CL, wherein one or more epitope-binding domains are linked to the C-terminus of the immunoglobulin heavy chain, and/or one or more epitope-binding domains are linked to the C-terminus of the immunoglobulin light chain, methods for making such proteins, and uses thereof.Type: ApplicationFiled: May 26, 2010Publication date: March 15, 2012Inventors: Thil Dinuk Batuwangala, Laurent Jespers, Michael Steward
-
Publication number: 20120058530Abstract: This invention relates to the biocatalysts for the efficient production of succinic acid and/or other products from renewable biological feedstocks. The biocatalysts have a very high efficiency for the growth-coupled production of succinic acid and/or other products from carbohydrate feed stocks as a result of both genetic manipulations and metabolic evolution. More specifically, certain biocatalysts of the present invention produce succinic acid at high titers and yield in mineral salts media during simple pH-controlled, batch fermentation without the addition of any exogenous genetic material. The genetic manipulations of the present invention are concerned with the energy-conserving strategies coupled with the elimination of alternative routes for NADH oxidation other than the routes for succinic acid production. The biocatalysts contain glucose-repressed gluconeogenic phosphoenol pyruvate carboxykinase (pck) depressed by genetic modifications and a genetically-inactivated phosphotransferase system.Type: ApplicationFiled: April 2, 2010Publication date: March 8, 2012Applicant: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION INC.Inventors: Xueli Zhang, Kaemwich Jantama, Jonathan C. Moore, Laura R. Jarboe, Keelnatham T. Shanmugam, Lonnie O'Neal Ingram
-
Publication number: 20120058119Abstract: The present invention relates to TR21 polypeptides. In particular, isolated nucleic acid molecules are provided encoding human TR21 protein. TR21 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TR21 activity.Type: ApplicationFiled: November 14, 2011Publication date: March 8, 2012Applicant: Human Genome Sciences, Inc.Inventors: Steven M. Ruben, David Hilbert
-
Publication number: 20120058118Abstract: The invention relates to biparatopic A-beta binding polypeptides and, more specifically, to biparatopic A-beta binding polypeptides comprising at least two immunoglobulin single variable domains binding to different epitopes of A-beta. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as Alzheimer's Disease.Type: ApplicationFiled: March 2, 2011Publication date: March 8, 2012Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: John E. PARK, Cornelia DORNER-CIOSSEK, Stefan HOERER, Lothar KUSSMAUL, Martin LENTER, Katharina ZIMMERMANN, Gerald BESTE, Toon LAEREMANS, Pascal MERCHIERS, Jo VERCAMMEN
-
Publication number: 20120058223Abstract: A novel cold-active beta-galactosidase is enzyme specific for lactose. The enzyme is thus useful in e.g. the food industry for catalyzing at low temperatures the hydrolysis of lactose disaccharide into its constituent monosaccharides, glucose and galactose. A method produces the cold-active beta-galactosidase by recombinant DNA technology.Type: ApplicationFiled: February 9, 2010Publication date: March 8, 2012Applicant: Kobenhavns UniversitetInventors: Peter Stougaard, Mariane Schmidt
-
Publication number: 20120053232Abstract: Provided herein are isolated genomic polynucleotide fragments from the from the p15 region of chromosome 11 encoding human and tumor suppressing subtransferable candidate 4 (TSSC4) and methods of use.Type: ApplicationFiled: September 24, 2011Publication date: March 1, 2012Applicant: RYOGEN LLCInventor: James W. Ryan